CR Bard Inc. (BCR:NYSE)
Snapshot of CR Bard Inc. (BCR)
|
OPEN
--
|
PREVIOUS CLOSE
$80.72
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
01/22/09 - $88.43
|
52 WEEK LOW
04/23/09 - $68.94
|
|
|
MARKET CAP
7.8B
|
AVERAGE VOLUME 3 mo
654.3K
|
|
|
DILUTED EPS TTM
$4.99
|
SHARES OUTSTANDING
96.5M
|
|
|
EX-DATE
10/22/09
|
P/E TTM
16.2x
|
|
|
DIVIDEND
$0.68
|
DIVIDEND YIELD
0.84%
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
Wall Street analysts give their buy, sell, or hold views on various stocks in the news this week
Plus Wall Street analyst opinions on C.R. Bard and STEC
Plus Wall Street analyst opinions on C.R. Bard and STEC
Where do growth investors find promising stocks in a market stunted by recession and financial crisis?
related news
BCR Details
C. R. Bard, Inc. and its subsidiaries engage in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company’s vascular products include percutaneous transluminal angioplasty catheters, guidewires, introducers and accessories, peripheral stents, stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings used to treat stress urinary incontinence; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds used to treat prostate cancer; urine monitoring and collection systems; ureteral stents; fecal incontinence products; and specialty devices for ureteroscopic procedures and stone removal. The company offers various devices to treat and manage cancers, and other diseases and disorders, including specialty access catheters, ports, vascular access ultrasound devices, and enteral feeding devices. Its surgical specialty products include patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopaedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.
BCR Top Compensated Officers
Key developments for CR Bard Inc. (BCR)
CR board Inc. reported consolidated unaudited earnings results for third quarter and nine months ended September 30, 2009. For the quarter, the company reported net income of $130,000,000 and net income attributable to common shareholders of $129,500,000 or $1.31 per diluted share on net sales of $637,000,000 compared to net income of $112,100,000 and net income attributable to common shareholders of $111,200,000 or $1.08 per diluted share on net sales of $616,800,000 for the same period a year ago. Income from operations before income taxes was $185,200,000 compared to income from operations before income taxes of $161,300,000 for the same period a year ago. For nine months period the company reported net income of $355,600,000 and net income attributable to common shareholders of $354,200,000 or $3.52 per diluted share on net sales of $1,858,000,000 compared to net income of $269,000,000 and net income attributable to common shareholders of $267,100,000 or $2.59 per diluted share on net sales of $1,817,900,000 for the same period a year ago. Income from operations before income taxes was $508,000,000 compared to income from operations before income taxes of $386,000 for the same period a year ago.
CR Bard Inc. expected to Report Fiscal Year 2009 Results on January 25, 2010. This event was calculated by Capital IQ (Created on October 21, 2009).
CR board Inc. provided sales guidance for fourth quarter of 2009. For the quarter, the company expects constant currency sales growth of between 4% and 6%.
Stock Quotes
| Recently Viewed | |||
| BCR | $80.72 USD | 0.00 |  |
|---|---|---|---|
| TMX | $17.46 USD | +0.42 |  |
| AAPL | $199.92 USD | 0.00 |  |
Market data is delayed at least 20 minutes.
BCR Competitors
| Company | Last | Change |
| Coloplast | kr474.00 DKK | +1.50 |
| Edwards Lifesciences Corp | $81.25 USD | +0.12 |
| Getinge | kr136.00 SEK | +0.90 |
| Pall Corp | $32.25 USD | -0.10 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | BCR | Industry Range |
| Price/Earnings | 16.2x |
|
| Price/Sales | 3.1x |
|
| Price/Book | 3.6x |
|
| Price/Cash Flow | 15.5x |
|
| TEV/Sales | 2.8x |
|
|
BCR |
||
BCR transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Covington, GA-CR Bard
- Covington, GA-CR Bard
- Cranston, RI-CR Bard
- Covington, GA-CR Bard
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For CR Bard Inc. (BCR) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
